Alt-protein
-
DATABASE (44)
-
ARTICLES (132)
Lever VC was founded in 2018 by Nick Cooney, an early investor of Beyond Meat and Memphis Meats. He is also the co-founder of Good Food Institute. Lever has currently invested in 14 startups from the US, Europe, Asia and Latin America.Focused on investments in early-stage alternative protein companies, the firm announced the first close of its Lever VC Fund I in August 2020, with its fourth close at $46m in April 2021. The final close will be completed by June 2021. Investors in the fund include NFL and NBA athletes, British nobility, food businesses, alt-protein companies and family offices as limited partners.In June 2020, Lever launched a $28m joint investment fund and accelerator to invest in Chinese plant-based and cell-cultivated meat and dairy companies. The Lever China Alternative Protein Fund will invest RMB 40m in alt-protein companies in mainland China over the next four years.
Lever VC was founded in 2018 by Nick Cooney, an early investor of Beyond Meat and Memphis Meats. He is also the co-founder of Good Food Institute. Lever has currently invested in 14 startups from the US, Europe, Asia and Latin America.Focused on investments in early-stage alternative protein companies, the firm announced the first close of its Lever VC Fund I in August 2020, with its fourth close at $46m in April 2021. The final close will be completed by June 2021. Investors in the fund include NFL and NBA athletes, British nobility, food businesses, alt-protein companies and family offices as limited partners.In June 2020, Lever launched a $28m joint investment fund and accelerator to invest in Chinese plant-based and cell-cultivated meat and dairy companies. The Lever China Alternative Protein Fund will invest RMB 40m in alt-protein companies in mainland China over the next four years.
With a 55-tone capacity to produce fungi-based proteins annually, Mycorena’s Gothenburg facility will showcase its mycoprotein R&D and spur commercial expansion across Europe.
With a 55-tone capacity to produce fungi-based proteins annually, Mycorena’s Gothenburg facility will showcase its mycoprotein R&D and spur commercial expansion across Europe.
Bånt AB is the investment vehicle of Karl Sverker Forsén based in Luleå, a coastal city in Swedish Lapland. In May 2020, the Swedish family office invested in a Gothenburg startup Mycorena, a biotech that produces mycoproteins through fermentation. The fungi-based protein can be used as an alt-protein ingredient instead of traditional plant-based food components.
Bånt AB is the investment vehicle of Karl Sverker Forsén based in Luleå, a coastal city in Swedish Lapland. In May 2020, the Swedish family office invested in a Gothenburg startup Mycorena, a biotech that produces mycoproteins through fermentation. The fungi-based protein can be used as an alt-protein ingredient instead of traditional plant-based food components.
WWF-backed biotech Oceanium has developed a biorefinery that transforms seaweed into alt-proteins and compostable packaging that will soon be launched commercially.
WWF-backed biotech Oceanium has developed a biorefinery that transforms seaweed into alt-proteins and compostable packaging that will soon be launched commercially.
E²JDJ was founded in New Orleans in 2020 with an agtech and foodtech focus, including in the areas of cellular agriculture and synthetic biology. It has six startups in its portfolio and makes diverse investments. Its most recent disclosed investment was in the $4.7m July 2021 seed funding round of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions.
E²JDJ was founded in New Orleans in 2020 with an agtech and foodtech focus, including in the areas of cellular agriculture and synthetic biology. It has six startups in its portfolio and makes diverse investments. Its most recent disclosed investment was in the $4.7m July 2021 seed funding round of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions.
CEO and founder of Mycorena
Ramkumar Nair graduated in biotechnology at the Cochin University of Science and Technology in Kerala before going to Sweden for postgrad studies in 2013.During his PhD in industrial biotechnology at the University of Borås, he embarked on a research project to create fungi-based proteins from discarded sidestreams generated by food producers. After extensive research in 2017, he founded Mycorena in Gothenburg to produce mycoproteins using fermentation technology.The startup’s first commercial product, Promyc, is now being sold to global food companies as a more sustainable and nutritional alt-protein compared to traditional plant-based proteins.
Ramkumar Nair graduated in biotechnology at the Cochin University of Science and Technology in Kerala before going to Sweden for postgrad studies in 2013.During his PhD in industrial biotechnology at the University of Borås, he embarked on a research project to create fungi-based proteins from discarded sidestreams generated by food producers. After extensive research in 2017, he founded Mycorena in Gothenburg to produce mycoproteins using fermentation technology.The startup’s first commercial product, Promyc, is now being sold to global food companies as a more sustainable and nutritional alt-protein compared to traditional plant-based proteins.
CEO and founder of Plantruption
Jennifer O'Brien qualified as a financial advisor at University College Dublin in 2010. She started her banking career in 2007 at AIB where she spent six years working with SMEs and investments. In 2013, she joined KBC Bank Ireland as a restructures executive and went on to work as an asset manager at Link Asset Services in 2016. O’Brien also worked in asset management for two years at O’Dwyer Real Estate Management while completing an MBA at Trinity College Dublin. She left the realty company in 2019 to realize her dream to create alt-protein seafood using locally sourced seaweed.
Jennifer O'Brien qualified as a financial advisor at University College Dublin in 2010. She started her banking career in 2007 at AIB where she spent six years working with SMEs and investments. In 2013, she joined KBC Bank Ireland as a restructures executive and went on to work as an asset manager at Link Asset Services in 2016. O’Brien also worked in asset management for two years at O’Dwyer Real Estate Management while completing an MBA at Trinity College Dublin. She left the realty company in 2019 to realize her dream to create alt-protein seafood using locally sourced seaweed.
Founded in 2017 in Hong Kong, Happiness Capital invests in seed to growth stage companies in the US, Europe, Israel, and China, with a focus on issues affecting global happiness within the areas of citizen trust, food, health, climate change, and reduced inequalities. It hosts its own annual contest, the Super Happiness Challenge , a global open innovation contest to fund individuals and startups with ideas and new products or services that tapped into unmet needs to achieve happiness, with a possible $1m in total investment on offer. The VC currently has 37 startups in its portfolio, around half of which are in foodtech and agtech. Its most recent investments include leading the $4.7m July 2021 seed funding round of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions, and co-leading the $29m February 2021 Series A round of Israeli 3D printed alt-meat startup Redefine Meat.
Founded in 2017 in Hong Kong, Happiness Capital invests in seed to growth stage companies in the US, Europe, Israel, and China, with a focus on issues affecting global happiness within the areas of citizen trust, food, health, climate change, and reduced inequalities. It hosts its own annual contest, the Super Happiness Challenge , a global open innovation contest to fund individuals and startups with ideas and new products or services that tapped into unmet needs to achieve happiness, with a possible $1m in total investment on offer. The VC currently has 37 startups in its portfolio, around half of which are in foodtech and agtech. Its most recent investments include leading the $4.7m July 2021 seed funding round of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions, and co-leading the $29m February 2021 Series A round of Israeli 3D printed alt-meat startup Redefine Meat.
Based in London, CPT Capital is the venture arm of private equity pioneer Jeremy Coller's private family office. Coller is the founder of Europe’s first private equity for secondaries in 1990. The British philanthropist has also established several business schools and the Jeremy Coller Foundation that aims to eliminate factory farming. In 2017, CPT Capital was founded to disrupt the food industry with investments in the alt-protein sector to create the “future of food and materials” like plant-based, recombinant and cell-cultured proteins.
Based in London, CPT Capital is the venture arm of private equity pioneer Jeremy Coller's private family office. Coller is the founder of Europe’s first private equity for secondaries in 1990. The British philanthropist has also established several business schools and the Jeremy Coller Foundation that aims to eliminate factory farming. In 2017, CPT Capital was founded to disrupt the food industry with investments in the alt-protein sector to create the “future of food and materials” like plant-based, recombinant and cell-cultured proteins.
Mitchell Presser is a New York-based lawyer. He is currently co-chair of global law service Morrison & Foerster’s Global Corporate Department and a partner in the firm’s M&A and Private Equity group, advising on agriculture, amongst other areas. He previously was a founding partner of Paine Schwartz, a US-based $1.2 bn private equity firm specializing in sustainable food chain investing from 2006 to 2014. His sole disclosed angel investment to date was an undisclosed sum in the pre-seed funding of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions,
Mitchell Presser is a New York-based lawyer. He is currently co-chair of global law service Morrison & Foerster’s Global Corporate Department and a partner in the firm’s M&A and Private Equity group, advising on agriculture, amongst other areas. He previously was a founding partner of Paine Schwartz, a US-based $1.2 bn private equity firm specializing in sustainable food chain investing from 2006 to 2014. His sole disclosed angel investment to date was an undisclosed sum in the pre-seed funding of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions,
Chairman of the Board, co-founder, co-inventor of NovoNutrients
Russell J. Howard has been co-founder and chairman of the board at NovoNutrients, a San Francisco biotech manufacturer of alt-protein produced using fermentation and CO2, and the research company Oakbio, since the latter’s foundation in 2009. During this period, for a year, Howard also worked as head of commercial strategy at Genome.One, a genetics startup. Howard is also on the board of executives of two Australian pharma companies, Immutep and NeuClone. Previously, between 1997 and 2009, he was CEO at California-based Maxygen, dedicated to the commercialization of molecular breeding and gene shuffling in protein. The year before that, Howard was president and scientific director at global pharma giant GSK in Santa Clara, and between 1994 and 1996, he held the same position at AFFYMAX Research Institute, working on new drugs research. Howard also held long-term research positions, heading up the laboratory at Palo Alto’s DNAX Research Institute of Molecular & Cellular Biology for six years, and earlier spent nine years at Bethesda’s National Institute of Allergy and Infectious Diseases (NIAID) working on identifying new malarial pathogens. The doctor of biochemistry from the University of Melbourne has over 140 peer-reviewed publications. Following his studies, Howard spent three years undertaking postdoctoral research at Australia’s WEHI (formerly the Walter and Eliza Hall Institute of Medical Research).
Russell J. Howard has been co-founder and chairman of the board at NovoNutrients, a San Francisco biotech manufacturer of alt-protein produced using fermentation and CO2, and the research company Oakbio, since the latter’s foundation in 2009. During this period, for a year, Howard also worked as head of commercial strategy at Genome.One, a genetics startup. Howard is also on the board of executives of two Australian pharma companies, Immutep and NeuClone. Previously, between 1997 and 2009, he was CEO at California-based Maxygen, dedicated to the commercialization of molecular breeding and gene shuffling in protein. The year before that, Howard was president and scientific director at global pharma giant GSK in Santa Clara, and between 1994 and 1996, he held the same position at AFFYMAX Research Institute, working on new drugs research. Howard also held long-term research positions, heading up the laboratory at Palo Alto’s DNAX Research Institute of Molecular & Cellular Biology for six years, and earlier spent nine years at Bethesda’s National Institute of Allergy and Infectious Diseases (NIAID) working on identifying new malarial pathogens. The doctor of biochemistry from the University of Melbourne has over 140 peer-reviewed publications. Following his studies, Howard spent three years undertaking postdoctoral research at Australia’s WEHI (formerly the Walter and Eliza Hall Institute of Medical Research).
San Francisco-based BOND is a spinoff of Kleiner Perkins and its original digital growth fund. BOND was launched in 2019, investing across market segments and geographies. To date, it has raised two funds totaling $3.3bn and currently has 32 portfolio companies. Its recent investments include Portuguese home physiotherapy tech SWORD, the world’s fastest-growing musculoskeletal solution, in June 2021 in a $85m Series C funding round; and co-leading the July 2021 $50m Series B round of US fungi-based alt-protein startup Meati Foods.
San Francisco-based BOND is a spinoff of Kleiner Perkins and its original digital growth fund. BOND was launched in 2019, investing across market segments and geographies. To date, it has raised two funds totaling $3.3bn and currently has 32 portfolio companies. Its recent investments include Portuguese home physiotherapy tech SWORD, the world’s fastest-growing musculoskeletal solution, in June 2021 in a $85m Series C funding round; and co-leading the July 2021 $50m Series B round of US fungi-based alt-protein startup Meati Foods.
Marinya Capital is the family office ofJohn B Fairfax from the Australian Fairfax family, who originally established Fairfax Media, a large media company. Marinya largely invests in property and agricultural businesses but has also made at least two investments in tech startups and in an Australian VC. Its most recent disclosed investments were in the $4.7m July 2021 seed funding round of NovoNutrients, the US-based biotech producer of alt-protein using fermentation and CO2 and other emissions, and in the $55m Series B round of Australia’s premier plant-based brand v2food in 2020.
Marinya Capital is the family office ofJohn B Fairfax from the Australian Fairfax family, who originally established Fairfax Media, a large media company. Marinya largely invests in property and agricultural businesses but has also made at least two investments in tech startups and in an Australian VC. Its most recent disclosed investments were in the $4.7m July 2021 seed funding round of NovoNutrients, the US-based biotech producer of alt-protein using fermentation and CO2 and other emissions, and in the $55m Series B round of Australia’s premier plant-based brand v2food in 2020.
Nutrinsect’s cricket flour is a 100% organic alternative protein containing twice the protein of soy, with an all-purpose natural fertilizer as its byproduct.
Nutrinsect’s cricket flour is a 100% organic alternative protein containing twice the protein of soy, with an all-purpose natural fertilizer as its byproduct.
Co-founder of Xampla
Tuomas Knowles is co-founder of Britain’s Xampla, producer of plant-based biodegradable plastics made from protein, which was founded in 2018 based on his team’s pioneering research. Knowles is a professor of physical chemistry and biophysics at Cambridge University, where he has worked since 2010 and manages the Knowles Lab which focuses on researching protein self-assembly underlying neurodegenerative disorders like Alzheimer's and Parkinson's disease. Knowles holds a PhD in Biophysics from the University of Cambridge and a degree in physics from ETH Zurich, a science and technology university.
Tuomas Knowles is co-founder of Britain’s Xampla, producer of plant-based biodegradable plastics made from protein, which was founded in 2018 based on his team’s pioneering research. Knowles is a professor of physical chemistry and biophysics at Cambridge University, where he has worked since 2010 and manages the Knowles Lab which focuses on researching protein self-assembly underlying neurodegenerative disorders like Alzheimer's and Parkinson's disease. Knowles holds a PhD in Biophysics from the University of Cambridge and a degree in physics from ETH Zurich, a science and technology university.
Meatable: Cell-based meat startup secures $47m Series A for scalable technology
The Dutch startup offers a pioneering technology for quickly scaling cell-based meat production while eliminating the need for animal-derived growth media
Kantox: Value for corporates, headache for banks
Moving beyond its initial remit of currency exchange, Europe's fourth-fastest growing fintech Kantox has garnered awards and financial sector hostility as it differentiates itself in a crowded marketplace
Situm Technologies: The Google Maps for indoors, where GPS fails
It uses AI and mobile robotics to create high-precision, low-cost indoor location tech that integrates data processed from multiple radio and inertial sensors
Place to Plug: Symbiosis in scaling with the electric vehicle sector
Launched commercially just five months ago, EV-charging infrastructure platform Place to Plug has already attracted attention from investors in Silicon Valley and Asia
Dorabot's aim for warehousing: No humans allowed
With a combination of AI, global partnerships and speed, Dorabot is leaping into the future
Dai Wei and his Ofo: Fighting till the last act?
How the college student who founded a global bike-sharing sensation also led it to the verge of bankruptcy through a string of mistakes
Zero 2 Infinity: Multibillion-euro business line launches into near space
Europe's only near space player using balloon technology targets high demand in a lucrative market, including space tourism
Why is it so hard for Chinese edtech startups to make money in an alluring market?
Parents’ willingness to pay and investors’ enthusiasm are not enough to ensure a profitable future for edtechs that still lack a viable business model
Fourier Intelligence: Quality rehabilitation robots at affordable prices
The startup has also launched an open-source platform to boost rehabilitation robotics and exoskeleton R&D and collaboration
Smart Agrifood Summit 2021: A global innovation ecosystem is needed to catch up with other sectors
Investors from SVG Ventures/THRIVE, Pinduoduo and others agree that players must join forces to boost agrifood tech investment, internationally and across the value chain
For equality in education, Odilo brings books in the cloud free to millions worldwide
The "Amazon for digital content" Spanish edtech startup delivers virtual libraries and classrooms to kids and adults worldwide
Ecertic Digital Solutions: A Spanish leader in online ID verification
The Spanish biometric tech startup offers online ID verification and tracked document solutions in a US$10 billion market set to double by 2022
QOA: Gourmet guilt-free chocolate, without the cocoa
Munich-based QOA transforms industrial food waste into vegan chocolate, enabling consumers to avoid the sustainability and ethical issues of cocoa production
Catalonia: Spain's fast-rising robotics hub and next opportunity
With the robotics sector on the rise in Catalonia, expect to see more growth ahead, driving opportunities in related segments, especially services
SoccerDream: World's first VR soccer training platform to launch in China, US
SoccerDream uses virtual reality to boost trainee players' performance on the field by 36% compared to their peers
Sorry, we couldn’t find any matches for“Alt-protein”.
POPULAR DATABASE
